Market and analyst sentiment on ImmunityBio, Inc. ( IBRX ) has waxed and waned since I have been watching the company starting back in late 2023 , prior to the approvalI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space.Analyst’s Disclosure: ...

Core Insights - ImmunityBio's stock closed at $5.52, reflecting a 39.75% increase due to strong revenue growth for Anktiva, positive oncology trial results, and new regulatory approvals [1] - The trading volume surged to 176 million shares, which is approximately 1,254% higher than the three-month average of 13 million shares [2] - Preliminary 2025 net product revenue for Anktiva is projected to be around $113 million, indicating a year-over-year growth of 700% and a quarterly growth of 431% [4] Company Performance - ImmunityBio has experienced a significant decline of 85% since its IPO in 2015 [2] - The positive news regarding Anktiva and bladder cancer drug trials is expected to bolster investor confidence and attract potential investors [5] Market Context - The S&P 500 and Nasdaq Composite both saw slight declines of 0.06% [3] - Other oncology drug developers, such as Iovance Biotherapeutics and Krystal Biotech, also experienced stock price increases of 6.31% and 1.07%, respectively, indicating a broader reassessment of the oncology sector [3]

PresentationGood morning, everyone, and welcome to the last day of the 2026 J.P. Morgan Healthcare Conference. My name is Ben Davis. I'm an associate with the Healthcare Investment Banking team at JPMorgan. And I'm pleased to introduce Richard Adcock, CEO; and David Sachs, CFO of ImmunityBio. Richard will be running through his presentation, after which we'll have some time for questions and answers.Richard AdcockPresident, CEO & Director Thank you. Thanks for everybody being here, and thanks, [ Benjamin ] ...

Key Points ImmunityBio announced this morning that it had reached a major enrollment threshold for one of its clinical trials. It also highlighted initial success in treating patients with Non-Hodgkin lymphoma with one of its next-gen therapies. These developments follow four other significant business updates from earlier this week that have helped the stock double in five days. 10 stocks we like better than ImmunityBio › Shares of cancer and infectious disease therapy developer ImmunityBio, In ...

ImmunityBio Inc. (NASDAQ:IBRX) stock has surged more than 100% year to date after the upbeat fourth-quarter preliminary results and trial data.Anktiva Trial UpdateThe company on Friday said enrollment exceeded internal expectations in its randomized registrational trial in BCG-naïve non-muscle-invasive bladder cancer (NMIBC), QUILT-2.005.Enrollment is now over 85% complete, with full enrollment of the planned study population anticipated by the second quarter of 2026.Based on the current enrollment trajecto ...

Core Insights - ImmunityBio Inc. (NASDAQ: IBRX) has experienced a significant increase in stock performance, with a 30.79% rise on Thursday, marking its 10th consecutive day of gains, driven by a 700% increase in preliminary revenues from Anktiva for the full year 2025 [1][3] Financial Performance - ImmunityBio reported $113 million in revenues from Anktiva, which is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer, indicating strong demand [2] - In the fourth quarter, ImmunityBio achieved $38.3 million in net revenues, reflecting a 431% increase compared to the same period last year [2] Sales Momentum - The company noted a quarter-over-quarter unit volume growth rate of 54% during FY 2025, indicating sustained sales momentum [3] - The approval from the Saudi Food and Drug Administration to market Anktiva in combination with an immune checkpoint inhibitor represents a strategic expansion opportunity for ImmunityBio in the Middle East [3][4]

Hedge funds don't need headlines to move — they need inflection points. ImmunityBio Inc (NASDAQ:IBRX) just delivered one. ImmunityBio stock has gone vertical, up nearly 96% year-to-date, but the real story isn't the stock move. It's the number behind it.Track IBRX stock here.On Thursday, ImmunityBio reported ~$113 million in 2025 revenue, marking a staggering 700% year-over-year increase — the kind of acceleration that turns early positioning into visible validation.The Revenue Inflection Hedge Funds Were P ...

Core Viewpoint - The article discusses the phenomenon of heavily shorted stocks, highlighting the reasons traders engage in short selling and the potential for short squeezes to create significant price movements in the market [2][3][4]. Group 1: Reasons for Heavy Shorting - Stocks become heavily shorted when experienced traders and institutional investors believe the company is fundamentally overvalued, anticipating a decline in its price [2]. - High short interest indicates a strong conviction among professional traders that the company faces serious risks [2]. Group 2: Short Squeeze Dynamics - Bullish traders, often retail investors, see high short interest as an opportunity for rapid gains through a short squeeze, which occurs when rising stock prices force short sellers to buy back shares, creating a feedback loop that drives prices even higher [3][4]. - The volatility associated with short squeezes can lead to returns that significantly exceed typical stock movements in a short time frame [4]. Group 3: Most Shorted Stocks - As of January 16, 2026, the top 10 most shorted stocks include: - Choice Hotels International, Inc. (CHH) with a short interest of 56.33% - Lucid Group, Inc. (LCID) at 54.45% - Avis Budget Group, Inc. (CAR) at 52.38% - Other notable companies include PureCycle Technologies, Inc. (PCT), Under Armour, Inc. (UAA), and Revolve Group, Inc. (RVLV) with short interests ranging from 39.22% to 41.89% [5][6][7].

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced an update on the status of enrollment in its randomized registrational trial in BCG-naïve non-muscle-invasive bladder cancer (NMIBC), QUILT-2.005. Enrollment has exceeded internal expectations and is now over 85% complete, with full enrollment of the planned study population anticipated by Q2 2026. Based on the current enrollment trajectory, ImmunityBio anticipates submitting a biologics license application (. ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety results from the ongoing QUILT-106 clinical study (NCT06334991) evaluating an off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy (CAR-NK). This CD19 t-haNK (CAR-NK) is a targeted high-affinity natural killer (NK) cell therapy engineered to express a CD19-specifc chimeric antigen receptor (CAR) used in combination with r ...